00 / pharma& news
We are proud to announce that we closed an agreement with Astellas Deutschland GmbH, (a subsidiary of Astellas Pharma Inc.) on December 31st 2021 to acquire Astellas’ worldwide rights* of Bendamustine commercialized under the brand names LEVACT®, RIBOMUSTIN® and others, securing access and continuous supply for patients benefitting from this well-established and distinguished therapy option.
For any inquiries please contact us at firstname.lastname@example.org.
*) excluding Marketing Authorizations in a small number of markets, including Morocco which is subject to merger clearance.
pharma& enters into a Strategic Partnership with Heritage Biologics Aimed at Improving Patient Access and Care.
Vienna, Austria and Kansas City, Missouri, USA on 30 July 2021.
zr pharma& GmbH (“pharma&”) today announced that its wholly-owned subsidiary, pharma& U.S. Inc., has entered into an agreement with Heritage Biologics, LLC (“Heritage Biologics”) acquiring 50% of the company’s shares.
Heritage Biologics and pharma& (advised by E3 Life) emphasized the strategic nature of the transaction, which offers substantial growth opportunities as well as synergies in securing access and improving clinical outcomes for patients with complex, often chronic, and rare conditions.
Tom O’Neill, owner and CEO of Heritage Biologics stated: “We look forward to fully leveraging pharma&’s network, its product acquisition pipeline, and access to capital to execute on Heritage Biologics’ ambitious growth plans.”
Elmar Zagler and Frank Rotmann, co-owners and officers of pharma& mentioned: “After intense scouting we are thrilled to have found in Heritage Biologics a US partner offering a strong foothold for our existing business together with significant upside potential in creating value for our stakeholders and patients alike”.
About Heritage Biologics:
Heritage Biologics is a home-infusion specialty pharmacy that specializes in the treatment of rare and chronic diseases. Our founders, unsatisfied with their own experiences and failures as rare-disease patients, understood that the only way to achieve higher outcomes and a better quality of life is through patient-centric care. Our team developed the world’s first pharmacy patient experience program, and from there, Heritage was born. From creating our own patient portal and data platform that provides care teams with real-time health analytics, to augmented reality devices that can help ensure better venous access, we have implemented tools that have engraved our legacy as pioneers in value based healthcare. For more information, please visit www.heritagebiologics.com.
pharma& is happy to announce that a share purchase agreement with Zatortia Holdings Ltd., Limassol, Cyprus (subsidiary of Shilpa Medicare Ltd., India) has been entered to acquire 100% of shares of LOBA Feinchemie GmbH, Fischamend, Austria.
This acquisition enables pharma& to vertically integrate a high-quality Active Pharmaceuticals Ingredient producer in order to secure long-term supply of its highly niche specialty care medicines. LOBA renews its firm commitment to the development and production of high quality Intermediates, Fine Chemicals and Active Pharmaceutical Ingredients and is looking forward to build upon the trusted and long-lasting customer relationships having been established in the past.
Continuing to build up our organisation, following the acquisition of Pegasys, pharma& is pleased to welcome Detlef Jakschies, PhD as Medical & Scientific Director. Detlef will be responsible for leading and implementing pharma&’s medical and scientific strategies, developing customized solutions to best serve the patients’ needs, with a focus on our worldwide business for Pegasys (Peginterferon alfa 2a).
Detlef joins us with a strong background in the field of Interferons, ranging from research at the Medical School of Hannover to various commercial roles in the pharmaceutical industry over the last 20 years, focussing on scientific leadership in the field of haematology and oncology. Respected and valued for his deep scientific understanding and clinical know-how, he is regarded as a valuable partner for his customers and peers alike and has established a strong network within the scientific community.
We are proud to announce that we recently signed an agreement
with F. Hoffmann-La Roche Ltd to acquire the worldwide rights of
Pegasys (Peginterferon alfa 2a) excl. China and Japan,
securing long-term access and supply for patients benefiting
from this well established therapy option.
For any inquiries please contact us at